EORTC partners with Pierre Fabre to support patients with stage 2 melanoma
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients with resected Stage 2 BRAF-mutant melanoma.